SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on October 20, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol BSGM. The report addresses a regulatory notice regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the closing bid price of the common stock failed to meet the $1.00 per share minimum for 31 consecutive business days between September 7, 2022, and October 19, 2022.
Material Changes
The primary material event is the receipt of a delisting warning letter from Nasdaq due to non-compliance with Listing Rule 5550(a)(2) regarding minimum bid price. There is no immediate impact on the listing; the stock continues to trade on The Nasdaq Capital Market.
Outlook, Risks, and Contingencies
- Compliance Period: The company has been granted an initial 180-day compliance period ending April 18, 2023, to regain compliance.
- Remediation Requirement: To cure the deficiency, the stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
- Secondary Compliance Option: If the initial period is unsuccessful, the company may qualify for an additional 180-day period if it meets all other initial listing standards (excluding bid price) and potentially effects a reverse stock split.
- Delisting Risk: If the company fails to cure the deficiency or is deemed ineligible for an additional cure period, Nasdaq will issue notice of delisting.
Investor Verification Checklist
- Verify the current trading price of BSGM to assess proximity to the $1.00 threshold.
- Monitor the company's stock price performance over the next 10 consecutive business days to determine if the initial cure condition is met.
- Review upcoming filings for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Check for any subsequent correspondence from Nasdaq regarding the status of the compliance period.